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Background and purpose: To apply target probabilistic planning (TPP) approach to intensity modulated
radiotherapy (IMRT) plans for head and neck cancer (HNC) patients.
Material and methods: Twenty plans of HNC patients were re-planned replacing the simultaneous inte-
grated boost IMRT optimization objectives for minimum dose on the boost target and the elective vol-
umes with research probabilistic objectives: the latter allow for explicit handling of systematic and
random geometric uncertainties, enabling confidence level based probabilistic treatment planning.
Monte-Carlo evaluations of geometrical errors were performed, with endpoints D98%, D2% and Dmean,
calculated at a confidence level of 90%. The dose distribution was expanded outside the patient to prevent
large bilateral elective treatment volumes ending up in air for probabilistic shifts.
Results: TPP resulted in more regular isodoses and in reduced dose, on average, to organs at risk (OAR), up
to more than 6 Gy, while maintaining target coverage and keeping the maximum dose to limiting struc-
tures within requirements. In particular, when the surrounding OARs overlap with the planning target
volume (PTV) but not with the clinical target volume (CTV), better results were achieved.
Conclusion: The TPP approach was evaluated in HNC patients, and proven to be an efficient tool for man-
aging uncertainties.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 109 (2013) 430–436Head and neck cancer (HNC) patients generally have very com-
plex target volumes, often large and overlapping with or in close
proximity to radio-sensitive critical structures [1]. The ability to
accurately shape dose in these patients becomes critical [2–4].
With intensity modulated radiotherapy (IMRT), treatments have
significantly improved in terms of organs at risk (OARs) sparing
while properly covering the target volumes [5]. This could allow
for dose escalation strategies on the gross tumor volume (GTV)
[6], e.g. using various tracers (such as 18[F]fluoro-deoxy-glucose
[7]) to identify the most radioresistant areas inside the GTV [8]
and drive the prescription dose distribution accordingly using
either a dose painting by contours (DPBC) [9] or a dose painting
by numbers (DPBN) [10] approach. For the latter, though, it is
inherently impossible to apply standard margin expansions for
the regions of interest (ROI) to account for uncertainties. Thesecan be separated in systematic (R) and random (r) components
[11]. The first correspond to the difference between the planning
geometry and the average geometry over all treatment fractions.
In our study the systematic errors included a systematic compo-
nent of setup uncertainty and a baseline shift. The latter are the dif-
ferences between the average treatment geometry and the day-to-
day geometries; the random errors refer to errors arising from the
positioning of the patient for each fraction. In recent years, many
techniques have been proposed to take such uncertainties into ac-
count during treatment planning optimization, e.g. probabilistic
treatment planning, PP [12–16]. Only our approach, though, allows
a confidence level (or probability) based plan optimization, pro-
ducing results directly comparable to the conventional margin-
based approach (for a detailed description of the method see
[17]). The purpose for this in silico planning study was to apply tar-
get PP (TPP) to HNC cases and to assess if the results obtained were
comparable with the traditional margin-based strategies. In case
they were not, why and to what extent they differ. This way, also
its application to DPBN planning, where no comparison with mar-
gin based planning is possible, can be considered reliable.
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Patient data
In this study, 20 patients were retrieved from the ROCOCO
database (www.mistir.info, [18]) who had undergone primary
radiotherapy for HNC and elective or therapeutic treatment of both
sides of the neck. The average age was 61 years (range 50–
80 years); 20% were female and 80% were male. The primary tumor
was located in the oropharynx and hypopharynx in 80% and 20% of
the cases, respectively. T-stage was T1 in 13% of the patients, T2 in
20%, T3 in 27% and T4 in 40%; N stage was N0 in 13% of the pa-
tients, N1 in 20%, N2a in 7%, N2b in 20% and N2c in 40%.
Radiotherapy treatment planning was performed on a research
version of the Philips Pinnacle3 treatment planning system (ver-
sion 9.100, Philips Radiation Oncology Systems, Fitchburg, WI,
USA). Dose was always calculated using the Adaptive Convolve
algorithm on computed tomography (CT) scans acquired in treat-
ment position with slice thickness of 2 mm.2 The three objectives are aimed at minimizing the quadratic distance between theGeometrical uncertainties
The original plans, according to the ROCOCO protocol, were cre-
ated with an expansion CTV to PTV of 0.5 cm in all directions. The
hospital values for the standard deviations (SD) of R and r were:
RX ¼ 1:11 mm
RY ¼ 1:10 mm
RZ ¼ 1:04 mm
8><
>:
rX ¼ 1:79 mm
rY ¼ 1:52 mm
rZ ¼ 1:68 mm
8><
>:
Patient position deviations were determined from Electronic Portal
Images (EPIs) of AP and lateral verification beams with respect to
the Digitally Reconstructed Radiographs of these beams. The EPIs
were acquired with Elekta iViewGT flat panels before start of treat-
ment. An off-line Shrinking Action Level (SAL) protocol [19] was
used for position correction with an initial action level of 6.2 mm
(3D vector length) which decreased to 3.1 mm after four fractions.
The position deviations of the vertebra were determined. 197
patients were analyzed. The hospital values for
P
and r were cal-
culated from the patient position deviations with off-line correc-
tions applied according to the method described in the appendix
of [20].
These values, according to [21], would produce a margin expan-
sion from CTV to PTV of:
MX ¼ 4:03 mm
MY ¼ 3:81 mm
MZ ¼ 3:77 mm
8><
>:
This is a margin not comparable to that used for the original plans,
which can be explained by the conservative approach of the ROCO-
CO protocol. But since the errors are then used in the TPP, for a fair
comparison they were re-scaled to produce a final margin as close
as possible to 0.5 cm.
So the values used were:
RX ¼ 1: mm
RY ¼ 1:42 mm
RZ ¼ 1:34 mm
8><
>:
rX ¼ 2:31 mm
rY ¼ 1:96 mm
rZ ¼ 2:17 mm
8><
>:Which would produce an anisotropic margin with values:
MX ¼ 5:19 mm
MY ¼ 4:92 mm





The original plans retrieved were IMRT plans created using the
Direct Machine Parameter Optimization (DMPO) module [22], with
seven coplanar 6-MV photon beams, at angles: 0, 50, 100, 150,
210, 260, 310, and a fixed collimator rotation of 5. To achieve
results as general as possible, independent from the specific LINAC
used, they were all reoptimized as pure fluence modulated plans,
without segmentation.
Organs at risk (OARs), including the parotid glands, submandib-
ular glands, spinal cord, brain stem, optic nerves, optical chiasm,
superior and middle pharyngeal constrictor muscle (PCM), and
supraglottic larynx, were outlined according to the previously de-
scribed guidelines [23,24]. The targets in the original plans, the
planning target volumes (PTVs), were created according to
[25,26]: a PTV54, prescribed with 54.25 Gy in 35 fractions of
1.55 Gy; and a PTV70 prescribed with 70 Gy in 35 fractions of
2.00 Gy. A simultaneous integrated boost (SIB) technique was used
where PTV54 was the prophylactic region and PTV70 was the ther-
apeutic region.Probabilistic planning
In the current work, the concept of PTV was discarded as in TPP
the uncertainties are handled without margin expansion. So we
created a copy of each of the originally delivered plans. Then we
discarded any objective on PTVs or PTV related structures such
as ring-like structures around or inside them (MinDose, MaxDose
and Uniform Dose objectives in Pinnacle2). We used instead the cor-
responding CTV54 and CTV70 (mean volumes 127 cm3 (range: 53–
327 cm3) and 376 cm3 (range: 254–327 cm3), respectively) as tar-
gets. As planning criteria, the ones in the original plans (correspond-
ing to the ROCOCO planning protocol) were used, with the same
weights. The same probabilistic coverage of the CTVs (evaluated
using the endpoints described in Section ‘Plan evaluation’) was re-
quested on both the original plans and on TPP. The maximum plan
dose was 77 Gy and no hotspots (dose exceeding 107% of the pre-
scribed dose) were allowed. After target coverage, the priority was
set to not exceed the maximum dose to critical structures (spinal
cord, 54 Gy; brainstem, 60 Gy; optic nerves, 54 Gy; and optic chiasm,
54 Gy). Finally, dose to other OARs was minimized as much as pos-
sible. In case of overlap between CTV and OAR, the overlapping re-
gion was considered as part of the tumor for the optimization
process. For each of the newly created plans, the DMPO optimization
was switched to Intensity Modulation, no conversion was applied
and, after resetting the beams and running the first optimization
procedure, two more warm runs (without beams reset) were per-
formed to refine the results.
The TPP plugin provided a research version of all the standard
optimization objectives in Pinnacle. We used a research objective
named MinDosePP: this is equivalent to the original MinDose
objective in Pinnacle, which is met when the region of interest
has a minimum dose that is greater than or equal to the target
dose. MinDosePP integrates also systematic and random geometric
uncertainties during each cost computation. Random errors were
simulated by blurring the dose while systematic errors byminimum, maximum and mean calculated dose and the prescribed dose, respectively.
432 Probabilistic planning for head and neckdisplacing the ROI with respect to the dose distribution. For every
ROI, a cost was calculated for each systematic error, and the prob-
ability associated with that error was used to weigh the contribu-
tion to the total cost. These contributions were then sorted by cost
value. Finally the effect of systematic errors with a certain confi-
dence limit P was calculated adding the cost of every systematic
error weighted with its probability until the sum of the probabili-
ties equals P (a more comprehensive description of the method
used can be found in [17]). We did not use multiple research objec-
tives on the targets because this would raise correlation problems.
In fact, shifts are applied at each cost calculation step and, if multi-
ple objectives independently pick random values from the errors
distributions, this would lead to the paradoxical situation of one
ROI potentially positioned in two or more different locations with
respect to dose distribution at each optimization step. Instead, we
used a feature of the plugin for dose painting by contours (named
‘‘ROIdelineation’’) which allows to set a double prescription value
on CTV54 and CTV70 in the same objective, thus avoiding all cor-
relation issues. No research objectives were set on OARs also to
avoid correlation issues.Plan evaluation
The probabilistic evaluation (PE) was performed at the end of
each optimization cycle described in Section ‘Probabilistic plan-
ning’: if the endpoints described in the following lines matched
the values obtained for the CTVs in the original plans, the proce-
dure was stopped. Otherwise it was repeated changing the objec-
tive weights until the endpoints matched.
The endpoints were calculated using a standalone software tool
(UncertLite, [11]). The tool has the following workflow:
1) 10.000 locations of a selected ROI are simulated relative to
the dose grid based on given R.
2) 35 random errors (according to the number of fractions) are
sampled from the random error distribution and consecu-
tively added to the systematic error. A cumulative dose is
constructed for each systematic error.
3) The delivered dose to the selected ROI is calculated for loca-
tions defined in step (1) and weighted according to the prob-
ability of each location.
4) The endpoints D99%, D98%, D2% and Dmean are calculated
based on the distribution of CTV doses at a confidence level
(CL) of 90%. This CL means that the calculated endpoint val-
ues are reached for at least 90% of patients from the popula-
tion with the given systematic and random errors.
Normalization to 35 fractions  2 Gy and alpha/beta ratio
of 10 Gy was performed.
The CTV54 volumes were smoothed inside Pinnacle using the
‘‘smooth contour’’ tool to produce a comparable volume estimate
in both Pinnacle and UncertLite which use slightly differentFig. 1. (a) CTV54 in a coronal projection showing its proximity to skin on both sides of th
(on the left) is expanded around the patient (on the right) enough to encompass all posvolume reconstruction methods: CTV54 is typically a very large
and complex ROI so it is likely that different results may be pro-
duced. Smoothing the contours reduces this effect and the final
volumes estimated by Pinnacle and UncertLite were identical.
Both the original and the TPP plans were evaluated with Uncert-
Lite for coverage of CTV54 and CTV70.
The dose to OARs was evaluated based on the static planned
dose distribution and the reported values were provided by the
dose evaluation tool of Pinnacle.Dose flash in air for evaluation
During plan evaluation, the CTVs were displaced relative to the
dose distribution according to systematic and random errors [27]
but if they were very close to the skin of the patient they might
end up in air. If their shape was wide and bilateral, as for CTV54
in these HNC patients (Fig. 1a), almost every shift on one side or
the other would bring the target outside the patient. This resulted
in unrealistic dose volume histogram (DVH) calculations for the
target. To overcome this issue, during evaluation the dose distribu-
tion was expanded around the patient (Fig. 1b). The assumption
was that shifting the whole patient and recalculating the dose in
the target would give a result comparable to shifting only the tar-
get inside the expanded dose distribution and recalculating the
DVH (as in [27]). The dose expansion to encompass all possible
shifts of the targets was performed by first eroding the dose by
0.7 cm inwards from the external contour of the patient to elimi-
nate the build-up region. This was then followed by a 1.5 cm lay-
ered expansion, filling each voxel of the layers from the patient
to the expanded contour with the maximum value of dose of the
neighboring voxels on the previous layer. A slightly modified ver-
sion of this approach was already presented in [28].Results
PTV54 and PTV70 received at least 95% of the prescribed dose
on 98% of their volumes for all the original plans and all patients,
according to the DVH reported by Pinnacle. Evaluation performed
with UncertLite of the original plans showed instead that for
CTV54 the coverage was systematically slightly lower than ex-
pected, with an average value of 94.1% of prescribed dose to 98%
of the volumes. For CTV70, on the other side, the coverage was sys-
tematically higher (except for one patient, number 1, where the
coverage resulted in only 93.8%), with an average value of 97.7%
of prescribed dose to 98% of the volumes. The corresponding TPP
plans were matching the original coverage values to an excellent
degree (Table 1).
The same coverage on CTVs, when evaluated with UncertLite,
was obtained only manually fine tuning the weights of the re-
search objectives on TPP plans. No threshold was set a priori on
this variation, as they were only intended to reproduce ase neck. (b) The original dose distribution as retrieved from the original Pinnacle plan
sible probabilistic shifts of the targets (dashed before the shift and solid after).
Table 1
Dose to 98% of the volumes of CTV54 (on the left) and CTV70 (on the right) as absolute values and as percent of the prescribed dose (54.25 Gy to CTV54 and 70 Gy to CTV70),
according to the evaluation performed with UncertLite. Average values and standard deviations are also reported, showing an excellent agreement between CTVs coverage in the
original plans and the PP ones.
CTV54 CTV70
Patient Original PP Original PP
Dose (Gy) V98 (%) Dose (Gy) V98 (%) Dose (Gy) V98 (%) Dose (Gy) V98 (%)
1 50.61 93.3 50.84 93.7 65.64 93.8 65.29 93.3
2 51.09 94.2 50.91 93.8 68.78 98.3 68.90 98.4
3 51.40 94.7 51.19 94.4 68.68 98.1 68.57 98.0
4 51.18 94.3 51.78 95.4 68.41 97.7 67.83 96.9
5 51.04 94.1 51.21 94.4 68.86 98.4 68.85 98.4
6 51.36 94.7 51.55 95.0 68.84 98.3 69.03 98.6
7 50.67 93.4 51.44 94.8 67.36 96.2 67.96 97.1
8 51.30 94.6 51.45 94.8 69.08 98.7 69.08 98.7
9 51.38 94.7 51.44 94.8 68.66 98.1 68.71 98.2
10 51.12 94.2 51.22 94.4 68.35 97.6 67.55 96.5
11 51.03 94.1 51.24 94.5 68.48 97.8 68.38 97.7
12 51.15 94.3 51.22 94.4 68.67 98.1 68.33 97.6
13 50.93 93.9 50.97 94.0 68.61 98.0 68.73 98.2
14 51.33 94.6 50.97 94.0 68.57 98.0 67.84 96.9
15 51.27 94.5 51.57 95.1 68.55 97.9 68.75 98.2
16 51.47 94.9 51.24 94.5 68.79 98.3 68.73 98.2
17 51.16 94.3 51.33 94.6 69.16 98.8 68.75 98.2
18 51.22 94.4 51.71 95.3 68.43 97.8 68.62 98.0
19 50.27 92.7 50.91 93.8 68.32 97.6 68.33 97.6
20 50.42 92.9 50.89 93.8 67.25 96.1 67.93 97.0
Average 51.07 94.1 51.25 94.5 68.37 97.7 68.31 97.6
SD 0.33 0.6 0.28 0.5 0.80 1.1 0.83 1.2
Fig. 2. On the left, one of the IMRT plans with PTV70 colorwashed in dark gray; the lines correspond to the different isodose levels 45, 60 and 68 Gy. On the right, the same
case planned with the probabilistic planning strategy. A better conformality and steeper gradients can be seen, resulting in improved OARs sparing.
D. Fontanarosa et al. / Radiotherapy and Oncology 109 (2013) 430–436 433accurately as possible the original CTV coverage. The optimization
time, with the hardware available (Philips 810x workstation), was
on average 9 min.
In most patients, TPP produced more regular and smoother iso-
doses. This is probably the result of the incorporation of systematic
uncertainties which, during optimization, produce a shift of dose
volumes and ROIs relative to each other: for each shift the discrep-
ancy between prescription and calculated dose is minimized. Thus
the dose peaks are smoothed more efficiently and hot and cold
spots are reduced (Fig. 2).
Replacing the objectives on PTVs in the original plans with a
combined MinDosePP objective on CTV54 and CTV70 (as described
in Section ‘Probabilistic planning’), and using the original weights
(or allowing for minimum variations around it on the research
objective to reproduce CTV coverage as described in the previous
paragraph) for the associated cost function, the maximum dose
to limiting structures was kept within requirements also in theTPP plans. The dose to OARs, instead, was reduced on average in
all patients for all the considered ROIs (Table 2).
The maximum dose reduction observed with TPP was up to
more than 6 Gy (for one of the submandibular glands, Table 2).
The mean dose to healthy tissues (patient minus CTVs) also re-
mained constant.
Discussion
We found that, with TPP, increased sparing of OARs could be ob-
tained relative to margin based planning, while the evaluation pro-
cedure showed a similar probability of effective CTV coverage for
both methods. In this study, the TPP approach showed beneficial
when it was applied to both CTV54 and CTV70, however it might
be specifically required in the application of DPBN. In that case,
TPP could be very useful to boost sub volumes of CTV70 that have
high positron emission tomography (PET) standard uptake values
Table 2
Average values for the twenty HNC patients of dose and dose variation (difference between the dose to the ROI in PP and the dose to the ROI in the original plan) to limiting
structures and OARs between the original plan and the PP over the whole treatment course. Min and max values are also reported, which show that only minor variations
unfavorable to PP (negative values) have occurred while the advantages (positive values) were important for some structures of some patients. In the last row, mean dose to
healthy tissues is reported. The last four columns show the percentage of patients obtaining a max dose variation between the original plan and the PP larger than 1, 2, 3 and 5 Gy
respectively for each reported ROI. The dose to OARs was evaluated based on the static planned dose distribution.



















































Brainstem 49.56 48.62 0.94 35.01 35.61 0.60 54.27 51.09 3.18 55 20 5 0





44.00 42.70 1.30 48.25 48.24 0.01 44.68 38.79 5.89 55 20 15 5
Parotid
contralateral
33.46 32.89 0.57 25.06 25.12 0.06 48.75 46.54 2.21 20 5 0 0
Submand.
ipsilateral
67.36 66.46 0.90 69.94 69.96 0.02 68.04 61.99 6.05 25 5 5 5
Submand.
contralateral





64.65 63.75 0.90 69.60 70.20 0.60 60.11 58.35 1.76 45 0 0 0
Middle PCM 62.40 61.28 1.12 49.53 49.73 0.20 68.50 64.12 4.38 45 20 5 0
Supraglottic
larynx
59.72 58.68 1.04 69.33 69.83 0.50 70.86 66.92 3.94 40 20 5 0
Healthy tissues (mean dose) 12.74 12.42 0.32 10.10 10.07 0.03 15.47 14.80 0.67 0 0 0 0
434 Probabilistic planning for head and neck(SUV) [6,8]. When the use of TPP is restricted to CTV70, due to its
limited extent and above all to the relatively small dose difference
between the prescription on CTV54 and CTV70, it is very difficult to
achieve substantial sparing on OARs surrounding CTV70 (and typ-
ically at least partially included in CTV54) and results produced by
TPP are likely to match those with margin-based planning.
Our results suggest that on average it is unlikely to achieve
important dose reductions to OARs when TPP is applied to targets
in HNC cases, but it is possible that specific patients benefit consid-
erably more than others. Typically, a good result is achieved on an
OAR when its contour overlaps with the original PTV of the target
but not with the CTV. In fact, in these cases, TPP producing steeper
isodose lines around the CTV can spare dose to the OAR. Typically
CTVs are surrounded by many OARs and the previous statement
cannot hold true for all of them simultaneously. However, for plan-
ning strategies aiming at sparing specific OARs (like swallowing
structures, for example), the overlap can be assessed for only those
structures and, if the requirement is satisfied, TPP can be consid-
ered to reduce dose to those organs. Moreover, it must be noted
that these results on OARs are also connected to our strict focus
on CTV coverage: as explained in Section ‘Probabilistic planning’,
the overlapping areas between targets and OARs were always con-
sidered by the optimizer as targets. So this work is presenting a
worst case scenario, whereas adopting a less aggressive approach
might result in a generally better sparing of healthy tissues.
As explained in Section ‘Probabilistic planning’, TPP was not ap-
plied on OARs because it was not possible to correlate the shifts
among the different research objectives. In inverse planning, it is
extremely complicated to take the correlation into account be-
cause the objectives are independently set. Nonetheless, it is advis-
able in the future to extend the PP to OARs, because small rotations
result in small differences at the isocenter, where the uncertainties
are typically calculated, whereas become important the larger is
the distance from it: so OARs located far from the target can possi-
bly show overdosage due to very small rotations. Dose is expected
to decrease rapidly moving away from the target, so this effect is
not likely to be important, in general. But for HNC patients wheretargets can extend considerably far from the isocenter, and thus
also steep dose gradients, this effect might be important. It would
be interesting also to apply PE on OARs, and it is part of our future
work: a systematic assessment of the impact of the uncertainties
on dose to OARs as a function of their magnitude and of the specific
OAR. Since there is now general consensus on the importance of lo-
cal variability of uncertainties for HNC patients [29–31], it would
be of extreme interest to assess how each specific structure is sen-
sitive to this variation. In this specific work, the application of PE
on OARs was not feasible because all the dose limits set on the ori-
ginal plans and by the ROCOCO protocol were set on OARs without
expansion. Therefore, the comparison between the ROIs with mar-
gin expansion in the original plans with the ROIs with probabilistic
shifts in the PP plans was not possible as we did for targets (where
the original dose constraints were set on the PTV while in TPP they
were set on the CTVs).
PP and PE applied to large targets (as is the case for the CTV54
presented here) in principle suffer from the same issues, because
the errors reported by the hospitals are calculated typically at
the beam isocenter: how to extend this information to surrounding
regions is in general unknown and patient-dependent for HNC
[31]. For example, head flexion with respect to the base of the neck,
tumor or parotid shrinkage or swallowing can create relatively
small differential displacements of the tissues which can in turn
result in dramatically different dose delivery: here in fact the large
targets require high dose levels in large areas. Therefore, in general,
errors have to be known very accurately, in particular in terms of
local variations, otherwise important dose misestimates might oc-
cur. It would be interesting to assess whether a population-based
uncertainty calculation is sufficient for these types of patients or
it is necessary to evaluate every single case separately. Paradoxi-
cally, small targets in areas undergoing much larger movements
than the head and neck region, such as non-small cells lung cancers
(NSCLC), require dose distributions less extended thus making
accuracy in tracking OARs positions less important. Moreover, in
lung cancer patients, respiratory motion can nowadays be pre-
dicted using 4DCT datasets [26], and deformation algorithms could
D. Fontanarosa et al. / Radiotherapy and Oncology 109 (2013) 430–436 435provide reliable estimates of error propagation patterns from the
target to every other tissue inside the patient.
In this work we assumed that the dose cloud approach is valid,
and that shifting the ROIs inside a static dose distribution is rea-
sonably similar to recalculating the dose after the shift. This
assumption was based on [28] where a similar approach as our
dose flash in air (there named Corrected Convolution) was imple-
mented, showing acceptable error levels also close to the surface.
The advantage of our approach, where the shifts are produced in
the dose space instead of fluence space, is in the calculation times:
in the first case, only the DVH must be computed, in the second for
each shift also a full dose re-calculation is required.
The approach we used was to reproduce on the TPP plans with
the highest possible accuracy the values of the endpoints for CTVs
of the original plans. Then we evaluated the doses on the OARs
using the standard tools provided by Pinnacle since, as discussed
previously, no extension of PE to structures other than targets
was feasible. So this can be considered a mixed approach, since a
proper evaluation should be performed with Monte Carlo methods
on all ROIs.
This work is based on a group of patients part of another study
previously published [32], where sufficient coverage of both PTV54
and PTV70 was reported. Our work shows that Monte-Carlo evalu-
ation can identify cases where the real coverage is not as expected
(see Table 1). It is necessary to highlight that CTV to PTV expansion
in the original plans was restricted to 0.5 cm from the skin to ex-
clude buildup region: so in this shallow area a prescription to
TPP CTVs and to the original PTVs do not aim at covering the same
area.
PP was previously applied to one HNC case [27], but with DPBN
approach, where no comparison with standard margins was possi-
ble and no extensive study of the characteristics of this site was yet
performed. Also, different methods were tested on HNC cases (see
for example [14]), but only the method used in this work imple-
ments a number of displacements sufficient to statistically account
for positioning errors. This allows an optimization with a given
confidence of a physical dose parameter, reproducing what is re-
quested with standard margin-based planning: thus a direct com-
parison with conventional planning strategies is possible, as
opposite to the other approaches (like the previously cited MIGA
[14], or based on coverage probabilities [12], or performing dose
error simulations prior to cost values computation [15]). Our
implementation of the optimization objectives is similar to the
coverage optimized approach introduced in [13], but adapted to
the Pinnacle environment.
The peculiarities of TPP applied to HNC cases were specifically
addressed in this work for the first time: very high and compli-
cated dose gradients, multiple extended complex targets and their
proximity to patient’s surface require solutions, presented here,
different than what is described elsewhere. For example, where
prostate cases are treated, as in [17] (where also rotations are con-
sidered) or [33] (where fractionation effect was not considered). In
these works, toxicity reduction thanks to PP was reported.
TPP provides on average a better sparing of OAR tissues, reduc-
ing the overlap area between the irradiated volume and the sur-
rounding structures. Categorizing plans according to OAR overlap
with PTV but not CTV potentially allows for an a priori assessment
of TPP strategy advantage over traditional margin based approach.
The dose to OARs was decreased without putting further efforts on
optimization: everything was kept as in the original plans, only one
objective was replaced by the research version, and minimal
weight changes were necessary for it to reproduce similar end-
points (as described in Section ‘Probabilistic planning’). This means
the decrease was due only to novel planning strategy. The benefit
of TPP is very dependent on individual patient factors, as is illus-
trated by the ranges in Table 1. More cases are being investigatedwithin the ROCOCO framework, allowing for comparison with
other treatment modalities.
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